Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

The Operational Reality of Reshoring Pharma Manufacturing: Q&A with Rohit Tripathi

ByNicholas Jacobus,Rohit Tripathi

August 20th 2026

How to Rebuild Pharma Operating Model for an AI Era

ByCharlie Paterson,Erik Nordkamp,Jenna Phillips

August 20th 2026

Pharmaceutical Executive Daily: President Trump to Nominate Heidi Overton as FDA Commissioner

ByNicholas Jacobus

August 19th 2026

A pricing decision made in London or Berlin can now affect U.S. reimbursement, tariff exposure, launch sequencing, manufacturing and capital allocation. After the Supreme Court limited the Administration's use of IEEPA for tariffs, Washington turned more heavily to Sections 232 and 301. Drug pricing now reaches beyond reimbursement. It is an enterprise strategy and trade question. Credit: Stock.Adobe.com/Alex Puhovoy.

When Drug Pricing Becomes Trade Policy

ByRon Lanton

August 19th 2026

President Trump Set to Nominate Heidi Overton as FDA Commissioner

ByNicholas Jacobus

August 19th 2026

Pharmaceutical Executive Digital Edition - May 2012

Articles in this issue

Related Content

The Operational Reality of Reshoring Pharma Manufacturing: Q&A with Rohit Tripathi

How to Rebuild Pharma Operating Model for an AI Era

Pharmaceutical Executive Daily: President Trump to Nominate Heidi Overton as FDA Commissioner

When Drug Pricing Becomes Trade Policy

President Trump Set to Nominate Heidi Overton as FDA Commissioner

Trending on PharmExec

When Drug Pricing Becomes Trade Policy

President Trump Set to Nominate Heidi Overton as FDA Commissioner

Pharmaceutical Executive Daily: Unpacking IRA-Driven Formulary Pressure

From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle

Pharmaceutical Executive Daily: President Trump to Nominate Heidi Overton as FDA Commissioner